Use of Double Aro Salmonella Mutants to Stably Express HPV16 E7 Protein Epitopes Carried by HBV Core Antigen

  • Patricia Londoño
  • Robert Tindle
  • Ian Frazer
  • Steve Chatfield
  • Gordon Dougan


Attenuated Salmonella strains have been used as vectors for delivering antigens from other pathogens via the oral. route1. These organisms are particularly efficient in eliciting mucosal. responses as well as cellular and humoral. responses against the heterologous antigen. Among the characterised of these attenuated Salmonella strains are genetically engineered aro mutants which are defective in one more of the genes required for the synthesis of aromatic compounds, including para-aminobenzoic acid and aromatic amino acids2. S.typhimurium aroA, aroD double mutants have been used as carriers to deliver a variety of heterologous antigens to the mammalian immune system. Examples are the P.69 Pertactin antigen of Bordetella pertussis 3 and tetanus toxin fragment C. The nucleocapsid of the Hepatitis B Virus (HBV), also known as core antigen, is a complex polymer made up of approximately 180 copies of a single 21KDa polypeptide which spontaneously assemble together into 27 nm diameter particles5. In spite of being internal. viral. antigens, the particles are very powerful humoral. and cellular immunogens6. An important feature of the core particles is their ability to provide T helper determinants for B lymphocytes directed against epitopes of other molecules physically linked to them7,8. This carrier ability has been exploited for eliciting immune responses against peptide sequences from different viruses. Chimeric core particles with inserted heterologous epitopes from human rhino virus, HBV, HIV and murine cytomegalovirus have been successfully used to elicit B and T cell responses in mice (for a review see 9). The strongest antibody responses were obtained when insertions were made in an immunodominant region of the protein known as the el loop. This region is thought to be an exposed loop structure accessible to the immune system in the surface of the core particle10.


Bordetella Pertussis Core Antigen Human Rhino Virus Heterologous Antigen Immunodominant Region 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    S. Chatfield, R.A. Strugnell, and G. Dougan, Live Salmonella as vaccines and carriers of foreign antigenic determinants, Vaccine 7: 495 (1989).PubMedCrossRefGoogle Scholar
  2. 2.
    S.K. Hoiseth, and B. Stocker, Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines, Nature 291:238, (1981).PubMedCrossRefGoogle Scholar
  3. 3.
    R. Strugnell, G. Dougan, S. Chatfield, I. Charles, N. Fairweather, J. Tite, J.L. Li, J. Beesley, and M. Roberts, Characterisation of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis, Infect Immun. 60:3994, (1992).PubMedGoogle Scholar
  4. 4.
    S. Chatfield, I. Charles, A. Makoff, M. Oxer, G. Dougan, D. Pickard, D. Slater, and N. Fairweather, Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral. vaccine strains: Development of a single-dose oral. tetanus vaccine, Bio-Technology 10: 888, (1992).PubMedGoogle Scholar
  5. 5.
    A. Budkowska, S.J. Wai-kuo, J.L. Gerin, Immunochemistry and polypeptide composition of hepatitis B core antigen (HBcAg), J Immunol. 118:1300, (1977).PubMedGoogle Scholar
  6. 6.
    K. Murray, S.A. Bruce, A. Hinne, Hepatitis B virus antigen made in microbial. cells immunises against viral. infection, EMBO J. 3:645, (1984).PubMedGoogle Scholar
  7. 7.
    D.R. Millich, A. McLachlan, A. Moriarty, Immune response to hepatitis B virus core antigen (HBcAg): Localisation of T-cell recognition sites within HBcAg/HBeAg, Immunology 139:1223, (1987).Google Scholar
  8. 8.
    B.E. Clarke, A.R. Carroll, M.J. Francis, Chimeric proteins based on hepatitis B core antigen form highly immunogenic particles, in. “Vaccines 89,” H. Ginsberg, F. Brown, R.A. Lerner, R.M. Chanock (eds), Cold Spring Harbor Laboratory, New York, (1988).Google Scholar
  9. 9.
    M.J. Francis, Use of hepatitis B core as a vehicle for presenting viral. antigens, Rev Human Biol. 1:62, (1992).Google Scholar
  10. 10.
    P. Arogs, and S. Fuller, A model for the hepatitis B core protein: prediction of antigenic sites and relationship to RNA virus capsid proteins, EMBO J. 7:819, (1988).Google Scholar
  11. 11.
    S. Comerford, D.J. McCance, G. Dougan, and J. Tite, Identification of B anti-cell epitopes of the E7 protein of human papillomavirus type 16, J Virol. 65:4681, (1991).PubMedGoogle Scholar
  12. 12.
    R.W. Tindle, J. Smith, H.Geysen, L. Selvey, and I. Fraser, Identification of B epitopes in human papillomavirus type 16 E7 open reading frame protein, J Gen Virol. 71:1347, (1990).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Patricia Londoño
    • 1
  • Robert Tindle
    • 3
  • Ian Frazer
    • 3
  • Steve Chatfield
    • 2
  • Gordon Dougan
    • 1
  1. 1.Department of Biochemistry ImperialCollege of Science, Technology and MedicineLondonUK
  2. 2.Vaccine Research Unit, Medeva Group ResearchImperial College of Science, Technology and MedicineLondonUK
  3. 3.Lions Immunology LaboratoryPrincess Alexandra HospitalBrisbane, QueenslandAustralia

Personalised recommendations